Session 80: Reports and Updates #1
Tuesday 19th October, 2021. 3PM EST/ 8PM GMT / 9PM CET
Giles Palmer and Dr. Magdalena Depa-Martynow
"Non-invasive Embryo Selection Through Metabolomics"
Dr. Santiago Munne (Sponsored by Overture Life)
"TMRW Today" with Dr. Cynthia Hudson
DR. SANTIAGO MUNNE
In 1993 he developed the first Preimplantation Genetic Test for Aneuploidy (PGT-A). As PGT director of IRMS-Saint Barnabas he developed PGT for translocations (1996, SART prize), and demonstrated that PGT-A reduces miscarriages and increases implantation rates (1998 SART prize). He is adjunct professor at Yale University Ob/Gyn Dept., published >260 scientific publications, received SART and ASRM prize papers, and the ASRM Star Award consecutively for 2011-2020.
In 2001 founded Reprogenetics with Jacques Cohen and David Sable, and as its CEO Reprogenetics became the first commercial US PGT laboratory, performing over 100K procedures
In 2017 he joined Martin Varsavsky and Joson Horcajadas to co-found Overture Life
, a company focused on automating the IVF Laboratory. He serves in several BOAs and BODs of private companies.
His talk is kindly sponsored by Overture Life
DR. MAGDALENA DEPA-MARTYNOW
Magdalena is an experienced embryologist. She was working more than ten years at Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics and Gynecological Oncology Poznan University of Medical Sciences, Poznan, Poland. Her interest at that time was predictive value of zygotes and early embryo assessment.
Magdalena received her Ph.D. at the Karol Marcinkiewicz University of Medical Sciences in Poznan in Poland. She was working on the determination the molecular basis of male infertility by indication of mRNA sperm transcripts and PRM1 and PRM2 proteins, which may influence on quality of human sperm, fertilization ability and early development of zygotes and embryos. She is an author of a numerous publications related with clinical embryology and assisted reproductive techniques.
Magdalena did a Canadian Executive Master of Business Administration study and obtained a diploma of ESG University of Quebec at Montreal UQAM and the Warsaw School of Economics SGH. She joined Reproductive Health, COOK Medical where, as a Clinical Specialist, she is combining scientific expertise with commercial knowledge in supporting both embryologists and internal company recipients.
As a working embryologist, entrepreneur, researcher, and industry expert, Cynthia Hudson, has built a unique skill set and singular perspective during her 20+ year career in the fertility space.
As Founder and CEO of Manhattan Fertility Services, Cynthia built and operated the first embryologist-owned, full-service fertility practice in New York City, while developing a pioneering patient experience and novel revenue streams. Her creation of a reference andrology lab, management corporation, and associated medical practice played a critical role in the center’s growth and eventual sale.
She applied this same holistic expertise as co-Founder of Kindbody — a revolutionary reproductive firm that combines best-in-class technology, clinical excellence, and accessible pricing — connecting the full patient experience on one intuitive platform.
In 2004, as Founder and CEO of Cellavita, Cynthia set the bar for Assisted Technology consulting services providing broad-based advisory and laboratory services for client IVF clinics in the U.S. and abroad.
Cynthia is a member of the Scientific Advisory Board for Hamilton Thorne, LTD, a leading global provider of precision instruments, consumables, software, and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets.
She is a member of the American Board of Bioanalysis, American Society for Reproductive Medicine, and American College of Embryology. As an active researcher, she has authored dozens of published contributions to leading scientific journals, such as Fertility & Sterility, Human Reproduction, and Science. Her work has also been featured in presentations at the American Society for Reproductive Medicine and the European Society for Human Reproduction and Embryology.
Giles is a clinical embryologist, skilled in laboratory, business, and quality management. After graduating in Genetics at Leeds University, UK he worked as a
research officer at London's Hammersmith Hospital's acclaimed IVF unit working with Professors Lord Winston and Alan Handyside. In the following years he worked as
laboratory manager and clinic director in IVF clinics in Greece while consulting in several countries including Iceland, Nigeria, and the Balkan states.
His research collaboration with St. Sophia' s Children's Hospital (Athens University) resulted in the first births in Greece following embryo-biopsy and pre-implantation genetic diagnosis. He has published in leading scientific journals on a variety of topics including pre-implantation genetic testing for Cystic Fibrosis and B-thalassaemia, Morpho-kinetics, and Quality Management. He is a certified HCPC clinical scientist in the UK and has been accredited with Senior Embryologist Status by ESHRE.
More recently, Giles, has become a consultant for IVF clinics, Institute of Life, Athens
and Nordica Fertility Centre in Lagos and product developer in a wide range of areas
within the industry.
He is the executive director for this non profit global educational project in Assisted Reproductive Technologies (ART), the International IVF Initiative.